CERENOVUS Neurothrombectomy Devices Registry

Inclusion Criteria:

1. Age ≥ 18

2. The participant or the participant's legally authorized representative has signedand dated an Informed Consent Form. In the event that local regulations allow foralternative approaches of consent, these must be fulfilled as approved by thesponsor and site's ethics committee/regulatory authority (if applicable)

3. Participants experiencing acute ischemic stroke with angiographic confirmation ofintracranial vessel occlusion

4. A clinical decision has been made to use a CERENOVUS neurothrombectomy device (EmboTrap® Revascularization Device, Large Bore Catheter/ EMBOVAC AspirationCatheter, or CEREGLIDE 71 Intermediate Catheter) independently and prior toenrollment in the research study

5. A CERENOVUS neurothrombectomy device is the first attempted primary device/techniquefor mechanical thrombectomy for the intracranial occlusion in the participant. Thefollowing primary devices/techniques are eligible for this study: a) EmboTrap®Revascularization Device alone b) EmboTrap® Revascularization Device + co-aspirationwith the Large Bore Catheter/EMBOVAC Aspiration Catheter or CEREGLIDE 71Intermediate Catheter c) EmboTrap® Revascularization Device + co-aspiration with anyother aspiration catheter d) Large Bore Catheter/EMBOVAC Aspiration Catheter alone (that is, direct aspiration with no stent retriever in the first attemptedtechnique) e) CEREGLIDE 71 Intermediate Catheter alone (that is, direct aspirationwith no stent retriever in the first attempted technique)

Exclusion Criteria:

1. Currently participating in an investigational (drug, device, etc) clinical trialthat may confound study endpoints. Patients in observational, natural history,and/or epidemiological studies not involving intervention are eligible

2. Confirmation of positive pregnancy test according to site specific standard of care (example, test, verbal communication)

3. Use of multiple stent retrievers on the first pass